Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 18/20 | 0.87 |
| ▸ | FKBP4 | Q02790 | 2/20 | 0.87 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.87 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.87 |
| ▸ | MLNR | O43193 | 1/20 | 0.87 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.87 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.87 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.87 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.87 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.87 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.87 |
| ▸ | HTR2A | P28223 | 1/20 | 0.87 |
| ▸ | HTR2B | P41595 | 1/20 | 0.87 |
| ▸ | MTOR | P42345 | 1/20 | 0.87 |
| ▸ | FKBP1B | P68106 | 1/20 | 0.87 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.87 |
| ▸ | PPP3CA | Q08209 | 1/20 | 0.87 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.87 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13528649 | 1.00 | FKBP1A (0.87) | FKBP1AFKBP4ABCB11ADORA3MLNR | |
| SCHEMBL12716478 | 1.00 | FKBP1A (0.87) | FKBP1AFKBP4ABCB11ADORA3MLNR | |
| SCHEMBL3103509 | 1.00 | FKBP1A (0.87) | FKBP1AFKBP4ABCB11ADORA3MLNR | |
| SCHEMBL3103515 | 1.00 | FKBP1A (0.87) | FKBP1AFKBP4ABCB11ADORA3MLNR | |
| SCHEMBL9696398 | 0.96 | FKBP1A (0.80) | FKBP1AFKBP4ABCB11ADORA3MLNR | |
| SCHEMBL6389097 | 0.95 | FKBP1A (0.86) | FKBP1AFKBP4ABCB11ADORA3MLNR | |
| SCHEMBL439470 | 0.94 | FKBP1A (0.86) | FKBP1AFKBP4ABCB11ADORA3MLNR | |
| SCHEMBL8780286 | 0.94 | FKBP1A (0.86) | FKBP1AFKBP4ABCB11ADORA3MLNR | |
| SCHEMBL24173142 | 0.94 | FKBP1A (0.95) | FKBP1AFKBP4ABCB11ADORA3MLNR | |
| SCHEMBL9240124 | 0.93 | FKBP1A (0.84) | FKBP1AFKBP4ABCB11ADORA3MLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2157429-A2 | Method of inhibiting nonspecific interaction between molecules on solid phase support | Reverse Proteomics Research Institute Co., Ltd (JP) | 2010-02-24 | — | — | EP | disclosed |
| US-7645614-B2 | Method of immobilizing compound on solid phase support | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2010-01-12 | — | — | US | disclosed |
| US-20080176341-A1 | Method for Suppressing Intermolecular Nonspecific Interaction and for Intensifying Intermolecular Specific Interaction on Metal Surface | REVERSE PROTEMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2008-07-24 | — | — | US | disclosed |
| US-20060177943-A1 | Method of inhibiting nonspecific interaction between molecules on solid phase support | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2006-08-10 | — | — | US | disclosed |
| US-20060024845-A1 | Method of immobilizing compound on solid phase support | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD (JP) | 2006-02-02 | — | — | US | disclosed |
| EP-1564555-A1 | METHOD OF IMMOBILIZING COMPOUND ON SOLID PHASE SUPPORT | Reverse Proteomics Research Institute Co., Ltd (JP) | 2005-08-17 | — | — | EP | disclosed |
| EP-1553412-A1 | METHOD OF INHIBITING NONSPECIFIC INTERACTION BETWEEN MOLECULES ON SOLID PHASE SUPPORT | Reverse Proteomics Research Institute Co., Ltd (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060177943-A1 | Method of inhibiting nonspecific interaction between molecules on solid phase support | CD2BP2, CD14, SPR | FKBP1A 1894/4885FKBP4 2051/4885ABCB11 3911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.